Adults and adolescents with severe nodular, cystic, or treatment-resistant acne may be prescribed Accutane. It contains isotretinoin, an oral retinoid that reduces sebaceous-gland activity and helps…
Adults and adolescents with severe nodular, cystic, or treatment-resistant acne may be prescribed Accutane. It contains isotretinoin, an oral retinoid that reduces sebaceous-gland activity and helps prevent new inflammatory lesions. The treatment requires individual dosing, pregnancy prevention, and laboratory monitoring.
Accutane contains isotretinoin, also known chemically as 13-cis-retinoic acid. It belongs to the retinoid class and acts throughout the body after oral administration. Unlike a topical retinoid, isotretinoin is absorbed into the bloodstream and affects sebaceous glands, follicular keratinisation, and inflammatory acne pathways.
The prescribed amount is individualised rather than fixed for every person. Dermatologists generally consider body weight, acne severity, response, adverse effects, lipid results, liver enzymes, and the amount of isotretinoin received across the entire course.
Common clinical principles include:
The cumulative dose describes the total amount received over the course, not the amount taken on one day. Clearing during the second month does not automatically mean that treatment can stop. The dermatologist may continue treatment to reduce the chance of early relapse, while also balancing dryness, laboratory changes, and other adverse effects.
Capsules should be taken exactly as prescribed. Some isotretinoin formulations are affected by food, so the correct relationship with meals depends on the specific formulation and prescribing instructions.
Monitoring commonly includes liver enzymes and blood lipids, especially triglycerides and cholesterol. Alcohol intake, diabetes, obesity, family lipid disorders, and medicines affecting the liver can influence these results.
Accutane contains isotretinoin, also known as 13-cis-retinoic acid. It is an oral retinoid that acts systemically after absorption into the bloodstream and affects sebaceous glands, follicular keratinisation, and inflammatory acne pathways.
Isotretinoin acts on several acne drivers at the same time. It reduces sebaceous-gland size and sebum output, changes the way skin cells accumulate inside follicles, decreases the conditions that support Cutibacterium acnes, and reduces inflammatory activity. These effects explain why isotretinoin can influence acne more deeply than a treatment aimed at only one pathway [1].
Sebum is the oily material produced by sebaceous glands. Excess sebum can combine with dead skin cells and obstruct the follicle. Isotretinoin reduces this oil flow, so new comedones and inflammatory lesions become less likely to develop.
Follicular keratinisation also changes. In plain language, the cells lining the pore are less likely to clump together and form a plug. Bacterial growth is affected indirectly because the follicle becomes less oily and less congested.
Accutane is intended for severe acne that causes deep nodules, cysts, persistent inflammation, or a meaningful risk of permanent scarring. It is also considered when acne has continued despite suitable topical treatment, oral antibiotics, or other dermatologist-directed approaches.
| Clinical situation | Main treatment goal | Usual clinical role |
|---|---|---|
| Severe nodular or cystic acne | Reduce active inflammation and prevent scarring | Specialist-prescribed systemic treatment |
| Treatment-resistant inflammatory acne | Control lesions after other approaches have failed | Individualised course |
| Acne with significant scarring risk | Reduce new lesions and limit further damage | Considered when benefits outweigh risks |
Mild comedonal acne is not the usual reason for prescribing Accutane. The treatment burden is substantial, so dermatologists balance acne severity, scarring risk, previous treatment response, mental-health history, laboratory findings, and reproductive considerations.
Some dermatological uses outside standard acne treatment have been studied or prescribed under specialist supervision. These uses require a separate clinical assessment and should not be inferred from the product name alone.
Several avoidable mistakes can make treatment harder or less predictable:
One practical issue is under-reporting joint or back pain. Mild aching may be manageable, but persistent pain, weakness, reduced mobility, or dark urine after strenuous exercise needs assessment.
Another is treating the first flare as proof that isotretinoin has caused permanent worsening. Early inflammation can occur, yet the prescriber may need to change the dose or provide additional short-term management.
Accutane may not be suitable if you could be pregnant, are planning a pregnancy, are breastfeeding, or cannot follow the required pregnancy-prevention and blood-test plan. Tell your prescriber if you have liver or lipid problems, significant mood symptoms, an allergy to the medicine, or take tetracycline antibiotics, vitamin A, or another retinoid.
Dryness is the most familiar effect of systemic isotretinoin. Chapped lips, dry facial skin, irritated eyes, and nasal dryness can appear during the early part of treatment. Nasal dryness may produce small nosebleeds, known medically as epistaxis.
Muscle and joint symptoms can also occur. Patients may describe aching after exercise, back discomfort, myalgia, or arthralgia. Severe, persistent, or worsening pain needs prompt medical review, especially when accompanied by weakness or reduced movement.
Blood-test changes can include raised triglycerides, known as hypertriglyceridaemia, and changes in liver enzymes. The risk is influenced by dose, individual metabolism, alcohol intake, pre-existing metabolic conditions, and other medicines.
Common practical measures include:
A temporary acne flare or “purge” can occur during the early weeks. This does not prove that the treatment is failing. A rapidly worsening eruption, painful swelling, or extensive inflammation should still be reviewed.
Accutane can increase sun sensitivity. A person who normally tolerates a short period outdoors may burn more quickly during treatment.
Mood changes require attention. Depression, anxiety, irritability, suicidal thoughts, or unusual behavioural changes should be reported urgently. A history of mental-health symptoms does not automatically rule out isotretinoin, but it requires careful assessment and follow-up.
| Treatment category | Main action | Typical limitation |
|---|---|---|
| Oral isotretinoin | Reduces sebaceous-gland activity and follicular blockage | Requires strict safety monitoring |
| Oral antibacterial treatment | Reduces bacterial and inflammatory activity | Relapse may occur after stopping |
| Topical retinoid treatment | Normalises follicular cell turnover at the skin surface | May be insufficient for deep nodular acne |
The reduction in sebaceous-gland activity is the feature most closely linked with longer-lasting remission. Skin may clear before the full treatment plan is complete, yet stopping early can leave the cumulative exposure below the dermatologist’s target.
Dermatologists generally view isotretinoin as a high-impact option for severe acne, not as a routine treatment for occasional spots. The decision depends on the expected scarring risk, previous treatments, the person’s medical history, pregnancy potential, and ability to complete monitoring.
A physician will usually set expectations before treatment begins. The skin can become drier before acne improves. New lesions may still appear during the first weeks. A successful course depends on taking the prescribed amount consistently and attending blood tests and follow-up appointments.
Laboratory monitoring is not a formality. Triglycerides can rise without obvious symptoms, and liver-enzyme changes may also be silent. A person can feel well while results still require a dose adjustment or temporary interruption. Follow-up visits help identify problems early.
Mental-health monitoring should be direct rather than vague. Changes in sleep, motivation, anxiety, irritability, or thoughts of self-harm deserve prompt discussion. The New Zealand regulatory framework and Medsafe safety information support careful risk management with isotretinoin [2].
Yes. Cheilitis, or inflammation and cracking of the lips, is one of the most common isotretinoin effects. Medsafe safety information and the EMA isotretinoin product information describe mucocutaneous dryness as an expected treatment issue, with regulatory documentation available before 2026. Frequent use of a bland, fragrance-free lip balm can reduce cracking, while severe swelling, infection, or bleeding needs medical review.
Take the missed dose when remembered unless the next scheduled dose is near. If the next dose is due soon, skip the missed dose and resume the normal schedule; do not double the amount. FDA prescribing information for isotretinoin, published in 2002, uses this approach for missed doses. Record repeated missed doses because the prescriber may need to reassess the course plan.
Early treatment can include dryness, a temporary flare, and continued new lesions before clearer improvement develops. The American Academy of Dermatology guidance published before 2026 supports reviewing adherence, dose, treatment duration, disease severity, and alternative causes when response is limited. Do not increase the amount independently, because adverse effects can rise without improving the outcome. A dermatologist may adjust the dose, extend the course, or investigate another skin diagnosis.
Alcohol can worsen triglyceride elevations and may add liver stress during isotretinoin treatment. Medsafe monitoring information and clinical prescribing practice before 2026 support limiting or avoiding alcohol, especially when lipid results or liver enzymes are abnormal. Heavy drinking before a blood test can make the results harder to interpret. Discuss any regular alcohol intake with the prescriber so monitoring can be planned accurately.
No. Isotretinoin is a potent teratogen, and pregnancy must be excluded before treatment and prevented reliably during therapy and for the required period afterward. WHO reproductive-health safety principles and isotretinoin regulatory requirements established before 2026 treat pregnancy exposure as a medical emergency requiring urgent specialist advice. Breastfeeding is also incompatible with treatment because the medicine may expose the infant.
Some people notice fewer inflamed lesions after several weeks, while others experience an early flare before improvement becomes clear. The EMA isotretinoin product information available before 2026 describes treatment as a course lasting several months rather than a rapid acne treatment. The full benefit is judged through follow-up examinations, lesion counts, scarring risk, tolerability, and cumulative exposure. Clearer skin in the early part of treatment does not necessarily mean the planned course is complete.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
My lips became dry during the first fortnight, and I needed balm several times a day. The acne settled gradually rather than overnight, but the painful lesions stopped appearing as often after the early flare.
Blenheim Over several months 6 Oct 2026The skin cleared well, although I disliked the dry eyes and stopped wearing contact lenses most days. My triglyceride result rose once, so the dermatologist reviewed my diet and dose before continuing.
Dunedin For several months 14 Oct 2026The course helped my face, but the first month was uncomfortable because of cracked lips and nasal dryness. I also had back aching after exercise and needed to reduce strenuous training for a while.
Greymouth Over several months 23 Oct 2026I noticed improvement after several weeks, then still had a few new spots later on. The pregnancy restrictions did not apply to me, but the blood tests and alcohol limitation were more demanding than I expected.
Taupō Over several months 3 Nov 2026
